| 000 | 01855 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516020142.0 | ||
| 264 | 0 | _c20110128 | |
| 008 | 201101s 0 0 eng d | ||
| 022 | _a1534-6080 | ||
| 024 | 7 |
_a10.1097/tp.0b013e3181ff1493 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHumar, Atul | |
| 245 | 0 | 0 |
_aExtended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. _h[electronic resource] |
| 260 |
_bTransplantation _cDec 2010 |
||
| 300 |
_a1427-31 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntiviral Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aCytomegalovirus Infections _xepidemiology |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aGanciclovir _xadministration & dosage |
| 650 | 0 | 4 | _aGraft Survival |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xblood |
| 650 | 0 | 4 |
_aImmunoglobulin M _xblood |
| 650 | 0 | 4 |
_aKidney Transplantation _xadverse effects |
| 650 | 0 | 4 | _aLikelihood Functions |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aSerologic Tests _xstatistics & numerical data |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aValganciclovir |
| 700 | 1 | _aLimaye, Ajit P | |
| 700 | 1 | _aBlumberg, Emily A | |
| 700 | 1 | _aHauser, Ingeborg A | |
| 700 | 1 | _aVincenti, Flavio | |
| 700 | 1 | _aJardine, Alan G | |
| 700 | 1 | _aAbramowicz, Daniel | |
| 700 | 1 | _aIves, Jane A L | |
| 700 | 1 | _aFarhan, Mahdi | |
| 700 | 1 | _aPeeters, Patrick | |
| 773 | 0 |
_tTransplantation _gvol. 90 _gno. 12 _gp. 1427-31 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/tp.0b013e3181ff1493 _zAvailable from publisher's website |
| 999 |
_c20484000 _d20484000 |
||